Pycnogenol: History and Discovery

Pycnogenol is not an ancient folk remedy with a thousand-year pedigree — it is a twentieth-century product of laboratory chemistry, and its real history is the story of one researcher and one class of plant compounds. The thread begins with a French chemist named Jacques Masquelier, who in 1947 isolated a family of polyphenols that he eventually called oligomeric proanthocyanidins (OPCs), and who later worked out how to extract them from the bark of the French maritime pine. A picturesque legend — the survival of Jacques Cartier's scurvy-stricken crew in 1535 after drinking a conifer-bark tea — is often told as Pycnogenol's origin story, but the honest record shows that link is inspirational rather than direct. This article separates the documented facts (a 1947 discovery, a 1951 pine-bark patent, a trademarked extract built on a defined polyphenol profile) from the parts that are contested or merely legendary, and names the people genuinely tied to each step.

Table of Contents

  1. The Cartier Legend: Inspiration, Not Origin
  2. Jacques Masquelier and the 1947 Discovery
  3. From Peanut Skins to Pine Bark
  4. Naming the Compounds: OPCs and “Pycnogenol”
  5. Horphag, the Trademark, and the Maritime Pine Source
  6. Standardization and the USP Monograph
  7. The Modern Clinical Era
  8. What the History Does and Does Not Prove
  9. Research Papers and References
  10. Connections
  11. Featured Videos

The Cartier Legend: Inspiration, Not Origin

Almost every popular account of Pycnogenol opens with the same dramatic scene. In the winter of 1535–1536, the French navigator Jacques Cartier and his crew were icebound near the site of present-day Quebec City on his second voyage to North America. Living on salted meat with no fresh fruit or vegetables, the men were struck down by scurvy — the vitamin C deficiency disease that loosens teeth, opens old wounds, and kills. By the depth of winter, by Cartier's own account, only a handful of his roughly one hundred men were still healthy and many had died.

What saved them was local knowledge. An Indigenous (Iroquoian / St. Lawrence Iroquois) informant showed the crew how to make a tea from the bark and needles of a North American evergreen the records call Annedda — the “tree of life.” The men recovered, and the episode became one of the most famous early encounters between European explorers and Indigenous plant medicine. The story is genuinely documented; it is the foundation of a careful modern review by Don J. Durzan, who weighed the historical, botanical, and biochemical evidence and concluded that the tree was most likely the eastern white cedar (Thuja occidentalis), while frankly admitting that the true identity of Annedda cannot be settled with certainty.

Here is where honesty matters. The tree that cured Cartier's crew was a North American conifer — almost certainly not the French maritime pine from which Pycnogenol is made — and the recovery is best explained by the high vitamin C content of fresh conifer needles and bark, not by proanthocyanidins. The Cartier story is told here because it is the historical seed that, centuries later, is said to have caught the imagination of the chemist who isolated OPCs. It is a piece of inspirational lore, not the literal discovery of Pycnogenol. Anyone who presents the 1535 tea as “the first use of pine bark extract” is blending a real history with a modern product that did not exist for another four hundred years.

Back to Table of Contents

Jacques Masquelier and the 1947 Discovery

The genuine scientific history of Pycnogenol begins with one named person: Jacques Masquelier (1922–2009), a French chemist and pharmacognosist at the University of Bordeaux. In 1947, as a young doctoral researcher, Masquelier isolated a colorless fraction of polyphenolic compounds and began the decades-long work of characterizing them. This 1947 date is the firmest anchor in the whole story and is the one most reference sources agree on: it is the year the class of compounds at the heart of Pycnogenol was first identified.

The compounds Masquelier had found belong to the flavonoid family — specifically chains (oligomers) built from catechin and epicatechin units, the same kind of molecules that give red wine, dark berries, and tree bark their astringency and color. He spent the rest of his career studying their chemistry and their effects on blood vessels and connective tissue, and he is widely and correctly credited as the pioneer of the whole field of proanthocyanidin research. Where the popular literature tends to drift is in compressing his long career into a single tidy moment; in reality the discovery (1947) and the maritime-pine product that the public now knows came years apart, through several changes of plant source.

Back to Table of Contents

From Peanut Skins to Pine Bark

One detail that almost every short summary gets wrong is which plant Masquelier worked with first. According to the histories told by Masquelier's own scientific lineage, the original 1947 material was not pine bark at all but the thin red skins of peanuts (groundnuts) — a cheap and abundant by-product in post-war France, which imported large quantities of West African peanuts. From those skins he obtained his first proanthocyanidin fraction.

The switch to pine came for a mundane, commercial reason. Around 1950, Senegal — then a major supplier — began exporting peanuts already shelled and skinned, cutting off the supply of the red skins Masquelier had been using. Needing a new raw material, he turned to the bark of the French maritime pine (Pinus pinaster), abundant in the great planted forests of Les Landes in southwestern France, and found it rich in the same OPC compounds. He patented a process for extracting proanthocyanidins from pine bark in 1951, and much later patented an extraction from grape seeds (commonly dated to 1970). This is why Pycnogenol and grape seed extract are so often called “sibling” OPC products: they descend from the same researcher and the same chemistry, separated mainly by their plant source.

The careful version of this story, then, is a sequence: peanut skins (1947) → maritime pine bark (patented 1951) → grape seeds (patented around 1970). The widely repeated shorthand that “Masquelier discovered OPCs in pine bark in 1947” collapses three real steps into one and gets the first plant wrong.

Back to Table of Contents

Naming the Compounds: OPCs and “Pycnogenol”

Two names from this history are routinely confused, and the difference is the single most useful thing to understand about the word “Pycnogenol.”

The first name is the scientific one: oligomeric proanthocyanidins, or OPCs — the general chemical class Masquelier studied, which occurs in pine bark, grape seed, cocoa, berries, and many other plants. The second is the word “pycnogenol” itself. The term is built from Greek roots — pyknos (πυκνóς), meaning “dense,” “thick,” or “condensed,” combined with a suffix marking it as a phenolic compound. The Oxford English Dictionary's earliest recorded use of the word comes from a 1979 paper by J. Masquelier, who appears to have coined “pycnogenols” (lowercase, plural) as a tidy collective name for this dense class of condensed flavanol compounds.

Over time the word split in two. Used generically and in the older literature, pycnogenols meant the whole OPC class. Capitalized and trademarked, Pycnogenol® came to mean one specific commercial product: the standardized French maritime pine bark extract. The exact attribution of the brand name is reported variously — some accounts credit the chemist Masquelier with the word, others credit the company that commercialized the extract — so this page treats the documented OED date (a 1979 Masquelier paper for the term itself) as firm, and treats the precise question of who first applied it as a brand as contested. What is not contested is the practical meaning today: lowercase “pycnogenols” is a chemistry word; capitalized “Pycnogenol” is a trademark.

Back to Table of Contents

Horphag, the Trademark, and the Maritime Pine Source

The transformation of Masquelier's pine-bark chemistry into the branded supplement sold worldwide was the work of a company, not a lone inventor. Horphag Research — founded by the entrepreneur Charles Haimoff and now based in Geneva, Switzerland, with the trademark held through Horphag Research Ltd. (Guernsey) — became the holder of the Pycnogenol trademark and the exclusive worldwide supplier of the extract. In the United States its applications are protected by patents (commonly cited as U.S. Patents 5,720,956 and 6,372,266) covering the extract and its uses.

The raw material is deliberately narrow. Pycnogenol is made only from the bark of the French maritime pine (Pinus pinaster ssp. atlantica) grown in the Les Landes de Gascogne forest of southwestern France — a vast, single-species planted forest where the trees are cultivated without pesticides or herbicides. Tying the product to one species from one region is not marketing decoration; it is what makes the extract's polyphenol composition consistent enough to study, which is the bridge to the next part of the story.

Back to Table of Contents

Standardization and the USP Monograph

What separates Pycnogenol from ordinary “pine bark extract” — and what made its later research possible — is standardization. Because Horphag controls a single-origin raw material and a fixed water-based extraction, every batch is held to a defined polyphenol profile: roughly 65–75% procyanidins by weight, with the balance made up of smaller flavonoids (catechin, epicatechin, taxifolin) and phenolic acids. That consistency is formalized in a monograph in the United States Pharmacopeia (USP): only material meeting the patented process and the monograph specification may legally carry the Pycnogenol name.

This is the quiet but decisive turn in the history. A traditional herbal preparation varies from batch to batch and from supplier to supplier, which makes its effects hard to pin down. By fixing the chemistry, Horphag turned a variable plant extract into a reproducible test article — the reason a trial done in one decade can be compared with a trial done in another, and the reason results from “Pycnogenol” cannot simply be assumed to transfer to a generic, unstandardized pine bark supplement.

Back to Table of Contents

The Modern Clinical Era

With a standardized product in hand, the late twentieth and early twenty-first centuries became Pycnogenol's clinical era. Researchers tested it for the things its chemistry suggested it should do — protect blood vessels, scavenge free radicals, support the connective tissue of veins and skin. A landmark in pulling this scattered work together was the year-2002 review by Peter Rohdewald of the University of Münster, which surveyed the extract's pharmacology and helped frame Pycnogenol as a single, well-characterized botanical medicine rather than a vague “natural antioxidant.” Today the manufacturer and reviewers describe a body of well over a hundred clinical studies and several hundred scientific publications, concentrated on chronic venous insufficiency and leg edema, endothelial function and blood pressure, skin and photoprotection, and attention and cognition.

The honest counterweight to that large literature is an independent Cochrane systematic review (Schoonees and colleagues, 2012), which pooled the randomized trials available at the time — fifteen small studies across seven different conditions — and concluded that the evidence was then insufficient to support claims of benefit in any single chronic disorder, largely because the trials were small and methodologically varied. The fuller, condition-by-condition picture of where the evidence is stronger and where it is thin is covered on the main Pycnogenol page; the point for a history is simply that Pycnogenol's modern reputation rests on accumulated clinical research, not on tradition, and that this research is genuinely large but still debated in quality.

Back to Table of Contents

What the History Does and Does Not Prove

It helps to end by saying plainly what this history establishes and what it does not. It establishes a clear chain of documented facts: a class of compounds (OPCs) identified by Jacques Masquelier in 1947; a shift from peanut skins to French maritime pine bark with a pine-bark extraction patent in 1951; a trademarked, standardized extract built on a defined 65–75%-procyanidin profile and a USP monograph; and a modern clinical literature of well over a hundred trials. These are real, datable milestones attached to real, named people and a real company.

It does not establish that Pycnogenol is an ancient remedy, that Cartier's crew were cured by it, or that its breadth of marketed uses is all proven — the Cartier link is inspirational legend, and the independent evidence reviews urge caution about sweeping claims. A history of a discovery is a reason to take a substance seriously and to study it; it is not, by itself, proof that the substance works for any particular purpose. Read this article for where Pycnogenol came from and who made it; read the main Pycnogenol page, and talk with a clinician, for what it can and cannot do.

Back to Table of Contents

Research Papers and References

The list below combines peer-reviewed sources on the chemistry, pharmacology, and evidence base of French maritime pine bark extract (Pycnogenol) with the historical paper on Cartier's scurvy episode and curated PubMed topic-search links. Author names, titles, and journals are given as plain text; only the stable DOI, PMID, or archive link is hyperlinked, and each opens in a new tab. The 1947 discovery date, the 1951 pine-bark and approximately 1970 grape-seed extraction patents, and the 1979 first recorded use of the word “pycnogenol” are documented in the secondary and reference literature cited and discussed in the article above.

  1. Rohdewald P. A review of the French maritime pine bark extract (Pycnogenol), a herbal medication with a diverse clinical pharmacology. International Journal of Clinical Pharmacology and Therapeutics. 2002;40(4):158–168. — doi:10.5414/cpp40158 · PMID: 11996210
  2. Durzan DJ. Arginine, scurvy and Cartier's “tree of life.” Journal of Ethnobiology and Ethnomedicine. 2009;5:5. — doi:10.1186/1746-4269-5-5 · PMID: 19187550
  3. Schoonees A, Visser J, Musekiwa A, Volmink J. Pycnogenol (extract of French maritime pine bark) for the treatment of chronic disorders. Cochrane Database of Systematic Reviews. 2012;(4):CD008294. — doi:10.1002/14651858.CD008294.pub4 · PMID: 22513958
  4. D'Andrea G. Pycnogenol: a blend of procyanidins with multifaceted therapeutic applications? Fitoterapia. 2010;81(7):724–736. — doi:10.1016/j.fitote.2010.06.011 · PMID: 20598812
  5. History of pine bark extract and oligomeric proanthocyanidins (OPCs) — PubMed: Pycnogenol maritime pine bark extract (reviews)
  6. Proanthocyanidins and OPC phytochemistry — PubMed: oligomeric proanthocyanidins (pine bark & grape seed)

External Authoritative Resources

Back to Table of Contents

Connections

Back to Table of Contents